The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Isatuximab-containing combination therapies for treating multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the use of isatuximab-based therapies for the treatment of patients with multiple myeloma (MM). Dr Cerchione outlines the value of isatuximab in combination with carfilzomib and dexamethasone (IsaKd) or pomalidomide and dexamethasone (IsaPd) in second-line treatment. He highlights some clinical trials assessing isatuximab combinations and expresses his interest in investigating how rechallenging with this agent may play a role in patients who have previously failed anti-CD38 antibody treatment. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
